New EU Regs Will Offer No Reprieve From Borderline Classification Chaos
Executive Summary
Challenges will persist for borderline and combination products under the new EU regulatory structure so manufacturers need to continue to pay close attention when determining the classification of these products.
You may also be interested in...
Fruitful Use Of EU Reg Loopholes Or Farce? How The Cranberry Is Dividing Opinions
The borders between medical devices, pharmaceuticals and even nutraceuticals are so fine that many companies seek to cross these subtle lines in order to gain regulatory or marketing advantage over their competitors. Often, this is achieved with success – although sometimes on shaky ground.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.